Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
cyteir2019-04-01T14:12:34-04:00Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors Novel, targeted, oral drug candidate inhibits DNA-repair protein to induce cell death in multiple cancer types including pancreatic cancer and B-cell non-Hodgkin lymphoma Preclinical data suggest CYT-0851 may overcome resistance to PARP inhibitors Data [...]